Every Form 4 that Novavax Inc (NVAX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NVAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NVAX filings page.
Novavax director Richard J. Rodgers reported equity compensation activity and an RSU vesting-related exercise. On June 20, 2026, he exercised 18,880 restricted stock units into 18,880 shares of common stock, bringing his direct common stock holdings to 47,370 shares.
Two days earlier, on June 18, 2026, he received grants of 14,180 new RSUs and 21,270 stock options with a $9.13 exercise price, each tied to the company’s Amended and Restated 2015 Stock Incentive Plan. Both the new RSUs and options vest 100% on the first anniversary of the June 18, 2026 grant date, subject to continued board service. The RSU exercise reflects full vesting of a prior June 20, 2025 RSU grant.
Novavax director Rachel K. King reported equity compensation activity and no share sales. On June 20, 2026 she exercised 18,880 restricted stock units (RSUs), receiving 18,880 shares of common stock, bringing her direct common stock holdings to 44,070 shares.
On June 18, 2026 she received two new awards under Novavax’s Amended and Restated 2015 Stock Incentive Plan: 14,180 RSUs and a stock option for 21,270 shares of common stock at an exercise price of $9.13 per share. The footnotes state that 100% of the new RSUs and option shares will vest on the first anniversary of the June 18, 2026 grant date, subject to her continued service on the board.
Novavax director Richard Douglas reported equity compensation activity, not open-market trading. On June 20, 2026, he exercised 18,880 restricted stock units, receiving the same number of Novavax common shares at no cash cost, bringing his direct holdings to 73,220 shares.
On June 18, 2026, he was granted 14,180 new restricted stock units and a stock option for 21,270 shares with a $9.13 exercise price. Footnotes state that 100% of these RSUs and options vest on the first anniversary of the grant date, subject to his continued service on the board.
Novavax director Margaret G. McGlynn reported equity compensation and an option exercise. On June 18, 2026, she received 14,180 Restricted Stock Units (RSUs) and 21,270 stock options, each RSU and option tied to one share of common stock. The options have a $9.13 per-share exercise price and will fully vest on the first anniversary of the grant date, subject to her continued board service.
On June 20, 2026, previously granted RSUs covering 18,880 shares vested and were exercised into the same number of Novavax common shares, leaving no remaining RSUs from that 2025 grant. After these transactions, she directly holds 44,468 shares of Novavax common stock. All reported activity reflects equity awards and vesting rather than any open-market buying or selling.
Novavax director David M. Mott reported equity compensation and an RSU vesting event. On June 18, 2026, he received grants of 14,180 Restricted Stock Units and a stock option for 21,270 shares of common stock with a $9.13 exercise price. Both awards vest 100% on the first anniversary of the grant date, subject to his continued service on the Board.
On June 20, 2026, 18,880 previously granted RSUs fully vested and were converted into 18,880 shares of Novavax common stock. Following this conversion, he directly holds 79,770 shares of common stock. These transactions reflect compensation-related awards and an option-style RSU conversion, with no open-market buying or selling.
Novavax director Gregg H. Alton reported equity compensation activity and an RSU vesting that increased his direct common stock holdings. On June 18, 2026, he received grants of 21,270 stock options with a $9.13 exercise price and 14,180 restricted stock units, each unit representing one share of common stock.
The footnotes state that 100% of these awards will vest on the first anniversary of the June 18, 2026 grant date, subject to continued board service. On June 20, 2026, 18,880 RSUs from a prior grant vested and were converted into the same number of common shares, bringing his direct holdings to 47,685 shares. All transactions are compensation-related grants and exercises, not open‑market purchases or sales.
Novavax director John W. Shiver received new equity awards as part of his board compensation. On June 18, 2026, he was granted 14,180 restricted stock units, each representing one share of Novavax common stock. He was also granted stock options on 21,270 shares at an exercise price of $9.13 per share.
Both the RSUs and the options were awarded under Novavax’s Amended and Restated 2015 Stock Incentive Plan. According to the terms, all of the shares subject to each grant vest on the first anniversary of the June 18, 2026 grant date, if he continues serving on the board through that date.
NOVAVAX INC director Charles W. Newton received new equity awards as part of his compensation. On June 18, 2026, he was granted 14,180 restricted stock units, each representing one share of Novavax common stock, and a stock option for 21,270 shares at an exercise price of $9.13 per share.
According to the company’s Amended and Restated 2015 Stock Incentive Plan, one hundred percent of the option shares will vest on the first anniversary of the June 18, 2026 grant date, subject to his continued service on the Board of Directors. The RSU grant is also described as vesting in full on the first anniversary of that grant date, under the same continued-service condition.
Novavax Inc. director Charles W. Newton acquired common shares through an RSU-related transaction. On April 25, 2026, he exercised derivative rights linked to Restricted Stock Units (RSUs), resulting in ownership of 9,520 shares of Novavax common stock held directly after the transaction.
Each RSU represents a contingent right to receive one share of Novavax common stock. According to the grant terms, the RSUs will vest in three equal annual installments, with one-third of the RSUs scheduled to vest on each of the first three anniversaries of April 25, 2025, subject to his continued service on the company’s Board of Directors.
Novavax, Inc. EVP of R&D Robert Edward Walker received new equity compensation awards. He was granted stock options covering 99,500 shares of common stock at an exercise price of $8.46 per share, expiring on April 14, 2036.
The option vests 25% on the first anniversary of the April 14, 2026 grant date, with the remaining 75% vesting in equal monthly installments over the following three years, subject to continued employment. He also received 66,000 restricted stock units, each representing one share of common stock, vesting in three equal annual installments over three years, also contingent on continued employment.
Novavax Inc. director John W. Shiver exercised restricted stock units and received additional common shares as part of his equity compensation. On March 10, 2026, he converted 7,947 RSUs into 7,947 shares of Novavax common stock at a price of $0.00 per share.
Following the transactions, Shiver directly holds 7,947 shares of common stock and 15,893 restricted stock units. The RSUs from this grant are scheduled to vest in three equal installments on each of the first three anniversaries of March 10, 2025, assuming he continues to serve on Novavax’s board through each vesting date.
Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity involving restricted stock units (RSUs) and common stock. On March 7, 2026, 12,223 RSUs were exercised and converted into 12,223 shares of Novavax common stock at a stated price of $0.0000 per share.
On the same date, 5,904 shares of common stock were withheld by the company at $9.98 per share to satisfy tax withholding obligations related to the RSU vesting, as noted in the footnotes. After these transactions, Kelly directly held 130,599 shares of Novavax common stock. A related footnote states that one-third of the RSUs from this grant vest on each of the first three anniversaries of the March 7, 2023 grant date, subject to continued employment.
Novavax Executive Vice President, CFO and Treasurer James Patrick Kelly reported an amended insider filing reflecting a grant of 194,000 non‑statutory stock options awarded on March 2, 2026. One-quarter of the options vest on the first anniversary of that date, with the remaining three-quarters vesting in equal monthly installments over the following three years, all conditioned on continued employment. The amendment only updates the exercise price previously reported; all other details remain the same, and the options are held directly.
NOVAVAX INC executive vice president of research and development Ruxandra Draghia-Akli reported an amended insider filing related to a previously disclosed stock option grant. On March 2, 2026, she was granted a non-statutory stock option covering 139,500 shares, held directly.
According to the filing, this Form 4/A was filed solely to amend the exercise price previously reported; all other information from the original March 5, 2026 Form 4 remains unchanged. One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.
Novavax Inc. executive Mark J. Casey reported an amended stock option grant. The Form 4/A updates only the exercise price originally reported for a non-statutory stock option covering 152,000 shares that was granted on March 2, 2026; all other details from the earlier filing remain the same.
The option was granted at no cash cost per option share and is held directly. One quarter of the 152,000 option shares vests on the first anniversary of March 2, 2026, and the remaining three quarters vest in equal monthly installments over the following three years, subject to continued employment.
NOVAVAX INC director and President and CEO John C. Jacobs reported a grant of 551,500 non-statutory stock options on March 2, 2026. This Form 4/A solely amends the exercise price originally reported in the prior Form 4; all other details are unchanged.
One quarter of the option vests on the first anniversary of March 2, 2026, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to continued employment.
Novavax executive Elaine O’Hara, EVP and Chief Strategy Officer, filed an amended Form 4 to correct the exercise price previously reported for a 2026 non-statutory stock option grant covering 177,500 shares awarded on March 2, 2026. All other details from the earlier filing remain unchanged.
Under this option, one-quarter of the shares vest on the first anniversary of March 2, 2026, and the remaining three-quarters vest in equal monthly installments over the following three years, subject to her continued employment with the company.
Novavax EVP, CFO and Treasurer James Patrick Kelly reported equity award activity. On March 3, 2026, he acquired 43,167 shares of common stock through the exercise and vesting of restricted stock units at no cost. On the same date, 20,850 shares of common stock were withheld by the company at $9.49 per share to cover tax obligations, leaving him with 124,280 directly held common shares.
Novavax Inc. President and CEO John C. Jacobs reported equity award activity. He exercised 150,167 Restricted Stock Units into an equal number of common shares at $0.0000 per share through a derivative conversion, then 69,288 common shares were withheld at $9.49 per share to cover tax obligations, leaving him with 225,680 common shares held directly.
Novavax executive Elaine O'Hara reported equity compensation activity involving restricted stock units and common shares. On March 3, 2026, she exercised or converted 56,334 restricted stock units, resulting in the acquisition of 56,334 shares of Novavax common stock at a stated price of $0.00 per share.
To cover tax withholding on this RSU vesting, 22,429 shares of common stock were withheld by the company at $9.49 per share, described as a tax-withholding disposition rather than an open-market sale. Following these transactions, O'Hara directly owned 134,642 shares of Novavax common stock. Footnotes state that one-third of the RSUs from this grant vest on each of the first three anniversaries of March 3, 2025, subject to continued employment.
Novavax EVP and Chief Legal Officer Mark J. Casey reported equity compensation activity involving restricted stock units and common stock. On March 3, 2026, 4,000 restricted stock units were converted and 37,500 shares of common stock were acquired through an exercise or conversion of derivative securities at a stated price of $0.00 per share.
In a related move, 11,378 shares of common stock were withheld at $9.49 per share to satisfy tax withholding obligations tied to the RSU vesting, leaving 90,067 shares of common stock held directly after these transactions. A footnote explains that one-third of the RSUs under the company’s 2015 Stock Incentive Plan vest on each of the first three anniversaries of March 3, 2025, subject to continued employment.
Novavax EVP of R&D Ruxandra Draghia-Akli reported new equity awards and related share movements. On March 2, 2026, she received 93,000 Restricted Stock Units and a non-statutory stock option for 139,500 shares at $9.09 per share, each vesting over several years subject to continued employment.
On March 3, 2026, 26,667 RSUs were converted into common stock, with the same number of RSUs disposed back to the company. To cover tax withholding on RSU vesting, 11,313 shares of common stock at $9.49 per share were withheld, leaving her with 23,563 common shares held directly.
Novavax, Inc. President and CEO John C. Jacobs reported multiple equity transactions. On March 2, 2026, he received a grant of 367,500 Restricted Stock Units and a grant of 551,500 Non-Statutory Stock Options with an exercise price of $9.09 per share, each subject to multi‑year vesting conditions.
On March 1, 2026, 83,333 Restricted Stock Units were exercised into 83,333 shares of common stock at $0.00 per share, and 38,450 shares of common stock at $10.14 per share were disposed of to satisfy tax withholding obligations related to RSU vesting. After these transactions, he directly owned 225,680 shares of Novavax common stock.
Novavax Inc. executive Kelly James Patrick, EVP, CFO and Treasurer, reported multiple equity compensation transactions. On March 2, 2026, he acquired 129,500 Restricted Stock Units (RSUs) and a non-statutory stock option for 194,000 shares at an exercise price of $9.09 per share.
On March 1, 2026, 58,666 RSUs were converted into an equal number of common shares, and 28,366 common shares at $10.14 per share were disposed of to cover tax withholding obligations. Footnotes state that prior RSUs vest in three equal annual installments from March 1, 2024, the new RSUs vest in three equal annual installments from March 2, 2026, and the stock options vest over four years starting on the first anniversary of March 2, 2026, all subject to continued employment.
Novavax EVP and Chief Strategy Officer Elaine O'Hara reported a series of equity-related transactions. She received a grant of 118,000 Restricted Stock Units (RSUs) and a stock option for 177,500 shares at an exercise price of $9.09 per share, both vesting over multi‑year periods subject to continued employment under the company’s stock incentive plan.
On the same dates, previously granted RSUs for 19,600 and 40,000 units were exercised into common stock. To satisfy tax withholding obligations tied to these vestings, 5,375 and 10,969 shares of common stock were disposed of at $10.14 per share, with the remaining shares held directly by O'Hara.
Novavax EVP and Chief Legal Officer Mark J. Casey reported several equity transactions. On March 2, 2026, he received a grant of 101,000 restricted stock units and a non-statutory stock option for 152,000 shares at $9.09 per share, both vesting over multiple years subject to continued employment.
On March 1, 2026, 4,000 restricted stock units were exercised into 4,000 shares of common stock, and 1,214 shares were withheld at $10.14 per share to cover tax obligations. Following these transactions, he continued to hold directly owned common stock and derivative awards tied to Novavax shares.
Jacobs John C reported disposition transactions in this Form 4 filing.
Novavax Inc. President and CEO John C. Jacobs exercised 83,197 Restricted Stock Units into an equal number of common shares on January 23, 2026. On the same date, 39,132 common shares were delivered to satisfy tax obligations. Following these transactions, he holds 180,797 common shares directly.
Novavax’s executive vice president and chief legal officer reported equity award activity involving company stock. On 12/11/2025, the executive acquired 41,899 shares of Novavax common stock at $0 per share, increasing direct ownership to 73,972 shares immediately after that transaction.
On the same date, a separate transaction coded “F” shows the disposition of 12,713 shares at a price of $6.69 per share, leaving the executive with 61,159 shares of common stock held directly. The filing also lists 41,899 restricted stock units tied to Novavax common stock at a $0 exercise price, with a vesting schedule under which one-third of the RSUs vest on each of the first three anniversaries of the grant date, subject to continued employment.
Novavax (NVAX) officer reported equity transactions on 11/11/2025. 14,257 shares of common stock were acquired at $0.00 via RSU conversion (Code M), and 6,048 shares were sold to cover taxes at $7.40 (Code F). After these transactions, 8,209 common shares were held directly.
The filing lists RSU activity tied to these shares and shows 28,513 restricted stock units beneficially owned following the transactions. Each RSU represents one share, with vesting at one‑third on each of the first three anniversaries of the grant date, subject to continued employment.
Novavax (NVAX) director reported an equity acquisition. On 10/29/2025, the reporting person acquired 3,800 shares of common stock through the settlement of restricted stock units (transaction code M). Following the transaction, the director beneficially owned 28,490 shares directly.
The RSUs were granted under the Company’s Amended and Restated 2015 Stock Incentive Plan and vest in three equal annual installments on each anniversary of the 10/29/2022 grant date, subject to continued employment. The derivative line shows 3,800 RSUs converted at $0.00 with 0 RSUs remaining from this grant after the transaction.